Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (891) 891
Publication (97) 97
Book Chapter (7) 7
Book Review (7) 7
Conference Proceeding (5) 5
Book / eBook (2) 2
Patent (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (405) 405
hematology (305) 305
female (247) 247
male (240) 240
index medicus (233) 233
middle aged (229) 229
aged (211) 211
adult (173) 173
oncology (159) 159
myelodysplastic syndromes (134) 134
aged, 80 and over (120) 120
prognosis (118) 118
treatment outcome (107) 107
myelodysplastic syndromes - drug therapy (101) 101
acute myeloid-leukemia (94) 94
myelodysplastic syndromes - genetics (82) 82
leukemia (71) 71
risk factors (66) 66
cancer (64) 64
adolescent (59) 59
myelodysplastic syndromes - mortality (53) 53
azacitidine (50) 50
hematology, oncology and palliative medicine (50) 50
mds (49) 49
myelodysplastic syndrome (49) 49
antimetabolites, antineoplastic - therapeutic use (48) 48
azacitidine - therapeutic use (48) 48
antineoplastic combined chemotherapy protocols - therapeutic use (47) 47
myelodysplastic syndromes - pathology (47) 47
abridged index medicus (46) 46
antineoplastic agents - therapeutic use (46) 46
life sciences (46) 46
chemotherapy (45) 45
survival (45) 45
survival rate (45) 45
myelodysplastic syndromes - therapy (44) 44
remission induction (44) 44
follow-up studies (42) 42
leukemia, promyelocytic, acute - drug therapy (42) 42
mutation (42) 42
risk (42) 42
classification (41) 41
therapy (41) 41
myelodysplastic syndromes - diagnosis (40) 40
survival analysis (40) 40
retrospective studies (39) 39
care and treatment (36) 36
disease-free survival (35) 35
karyotyping (35) 35
hemic and lymphatic diseases (34) 34
scoring system (34) 34
acute myeloid leukemia (32) 32
leukemia, myeloid, acute - drug therapy (32) 32
recurrence (32) 32
leukemia, myeloid, acute - genetics (31) 31
acute myelogenous leukemia (29) 29
mutations (29) 29
time factors (29) 29
trans-retinoic acid (29) 29
cytogenetics (28) 28
lenalidomide (28) 28
disease progression (27) 27
acute promyelocytic leukemia (26) 26
chromosome deletion (26) 26
colony-stimulating factor (26) 26
intensive chemotherapy (26) 26
leukemia, myeloid, acute - mortality (26) 26
research (26) 26
thalidomide - analogs & derivatives (26) 26
chronic myelomonocytic leukemia (25) 25
stem-cell transplantation (25) 25
analysis (24) 24
apoptosis (24) 24
thalidomide - therapeutic use (24) 24
decitabine (23) 23
expression (23) 23
tretinoin - therapeutic use (23) 23
young adult (23) 23
anemia (22) 22
international working group (22) 22
aml (21) 21
myelodysplastic syndromes - complications (21) 21
acute disease (20) 20
article (20) 20
child (20) 20
cytarabine - administration & dosage (20) 20
animals (19) 19
bone marrow - pathology (19) 19
efficacy (19) 19
france (19) 19
leukemia, myeloid - genetics (19) 19
translocation, genetic (19) 19
bone-marrow-transplantation (18) 18
cohort studies (18) 18
combined modality therapy (18) 18
conventional care regimens (18) 18
quality-of-life (18) 18
antineoplastic agents - adverse effects (17) 17
azacitidine - analogs & derivatives (17) 17
chromosome aberrations (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Azacitidine in untreated acute myeloid leukemia: A report on 149 patients
by Thépot, Sylvain and Itzykson, Raphael and Seegers, Valerie and Recher, Christian and Raffoux, Emmanuel and Quesnel, Bruno and Delaunay, Jacques and Cluzeau, Thomas and Marfaing Koka, Anne and Stamatoullas, Aspasia and Chaury, Marie‐Pierre and Dartigeas, Caroline and Cheze, Stéphane and Banos, Anne and Morel, Pierre and Plantier, Isabelle and Taksin, Anne‐Laure and Marolleau, Jean Pierre and Pautas, Cecile and Thomas, Xavier and Isnard, Francoise and Beve, Blandine and Chait, Yasmine and Guerci, Agnes and Vey, Norbert and Dreyfus, Francois and Ades, Lionel and Ifrah, Norbert and Dombret, Herve and Fenaux, Pierre and Gardin, Claude and ALFA and GFM and GOELAMS and Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS)
American Journal of Hematology, ISSN 0361-8609, 04/2014, Volume 89, Issue 4, pp. 410 - 416
Limited data are available on azacitidine (AZA) treatment and its prognostic factors in acute myeloid leukemia (AML). One hundred and forty‐nine previously... 
CONVENTIONAL CARE REGIMENS | 1ST-LINE TREATMENT | SUPPORTIVE CARE | INTENSIVE CHEMOTHERAPY | OLDER PATIENTS | PHASE-III | VALPROIC ACID | RISK MYELODYSPLASTIC SYNDROMES | TRANS-RETINOIC ACID | HEMATOLOGY | ELDERLY-PATIENTS | Azacitidine - adverse effects | Sepsis - etiology | Compassionate Use Trials | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Remission Induction | Antimetabolites, Antineoplastic - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Azacitidine - therapeutic use | Cohort Studies | Cytogenetics | Chemotherapy | Analysis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
by Castaigne, Sylvie, Prof and Pautas, Cécile, MD and Terré, Christine, MD and Raffoux, Emmanuel, MD and Bordessoule, Dominique, Prof and Bastie, Jean-Noel, Prof and Legrand, Ollivier, Prof and Thomas, Xavier, MD and Turlure, Pascal, MD and Reman, Oumedaly, MD and de Revel, Thierry, Prof and Gastaud, Lauris, MD and de Gunzburg, Noémie, MD and Contentin, Nathalie, MD and Henry, Estelle and Marolleau, Jean-Pierre, Prof and Aljijakli, Ahmad, MD and Rousselot, Philippe, Prof and Fenaux, Pierre, Prof and Preudhomme, Claude, Prof and Chevret, Sylvie, Prof and Dombret, Hervé, Prof and Acute Leukemia French Association
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9825, pp. 1508 - 1516
Summary Background The results of the addition of gemtuzumab ozogamicin, an anti-CD33 antibody conjugate, to the standard treatment for patients with acute... 
Internal Medicine | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | THERAPY | MYLOTARG | EFFICACY | RECOMMENDATIONS | SAFETY | INDUCTION | DAUNORUBICIN | IMMUNOCONJUGATE | CHEMOTHERAPY | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Male | Survival Rate | Antineoplastic Agents - therapeutic use | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antineoplastic Agents - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Aminoglycosides - adverse effects | Aminoglycosides - therapeutic use | Bone marrow | Chemotherapy | Mutation | Transplants & implants | Toxicity | Drug dosages | Thrombocytopenia | Intravenous administration | Motivation | Antibodies | Clinical trials | Platelets | Gemtuzumab ozogamicin | Survival | Antineoplastic Agents | Aminoglycosides | Leukemia, Myeloid, Acute | Life Sciences | Antibodies, Monoclonal, Humanized | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies
by Gandhi Damaj and Alain Duhamel and Marie Robin and Yves Beguin and Mauricette Michallet and Mohamad Mohty and Stephane Vigouroux and Pierre Bories and Alice Garnier and Jean El Cheikh and Claude-Eric Bulabois and Anne Huynh and Jacques-Olivier Bay and Faeyzeh Legrand and Eric Deconinck and Nathalie Fegueux and Laurence Clement and Charles Dauriac and Natacha Maillard and Jérôme Cornillon and Lionel Ades and Gaelle Guillerm and Aline Schmidt-Tanguy and Zora Marjanovic and Sophie Park and Marie-Thérèse Rubio and Jean-Pierre Marolleau and Federico Garnier and ierre Fenaux and Ibrahim Yakoub-Agha
Journal of Clinical Oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 36, pp. 4533 - 4540
Purpose To investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after allogeneic stem-cell transplantation (alloSCT) for... 
CONVENTIONAL CARE REGIMENS | SURVIVAL | FRENCH SOCIETY | ONCOLOGY | BONE-MARROW-TRANSPLANTATION | RISK | SINGLE-CENTER | EXPERIENCE | ACUTE MYELOID-LEUKEMIA | Azacitidine - adverse effects | Humans | Middle Aged | Induction Chemotherapy | Male | Treatment Outcome | Combined Modality Therapy | Myelodysplastic Syndromes - etiology | Antimetabolites, Antineoplastic - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Female | Retrospective Studies | Hematopoietic Stem Cell Transplantation - methods | Myelodysplastic Syndromes - surgery | Myelodysplastic Syndromes - drug therapy | Azacitidine - therapeutic use | Transplantation, Homologous - methods | Myelodysplastic Syndromes | Hematopoietic Stem Cell Transplantation | Transplantation, Homologous | Life Sciences | Immunology | Azacitidine | Antimetabolites, Antineoplastic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Myelodysplastic syndromes
by Adès, Lionel, MD and Itzykson, Raphael, MD and Fenaux, Pierre, Prof
Lancet, The, ISSN 0140-6736, 2014, Volume 383, Issue 9936, pp. 2239 - 2252
Summary Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by ineffective haemopoiesis leading to blood cytopenias, and by... 
Internal Medicine | CONVENTIONAL CARE REGIMENS | DUSSELDORF MDS-REGISTRY | PROGNOSTIC SCORING SYSTEM | MEDICINE, GENERAL & INTERNAL | COLONY-STIMULATING FACTOR | IRON CHELATION-THERAPY | BONE-MARROW-TRANSPLANTATION | DOSE ARA-C | ACUTE MYELOID-LEUKEMIA | TRANSFUSION-DEPENDENT PATIENTS | STEM-CELL TRANSPLANTATION | T-Lymphocytes - physiology | Diagnosis, Differential | Prognosis | Humans | Treatment Outcome | Antineoplastic Agents - therapeutic use | Mutation - genetics | Myelodysplastic Syndromes - etiology | Myelodysplastic Syndromes - diagnosis | Myelodysplastic Syndromes - therapy | Stem Cell Transplantation - methods | Epigenesis, Genetic - genetics | Hematopoiesis - physiology | Cytogenetic Analysis | Myelodysplastic syndromes | Transplants & implants | Gene expression | Clinical outcomes | Genotype & phenotype | Chemotherapy | Older people | Medical prognosis | Bone marrow | Epigenetics | Cytogenetics | Mutation | Tumors | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
by Kantarjian, Hagop and O'Brien, Susan and Ravandi, Farhad and Cortes, Jorge and Shan, Jianqin and Bennett, John M and List, Alan and Fenaux, Pierre and Sanz, Guillermo and Issa, Jean‐Pierre and Freireich, Emil J and Garcia‐Manero, Guillermo
Cancer, ISSN 0008-543X, 09/2008, Volume 113, Issue 6, pp. 1351 - 1361
BACKGROUND. Recent studies have highlighted issues with the International Prognostic Scoring System (IPSS) model in relation to the exclusion of many subgroups... 
prognosis in MDS | prognostic models | risk groups in MDS | chronic myelomonocytic leukemia | Prognosis in MDS | Prognostic models | Chronic myelomonocytic leukemia | Risk groups in MDS | SURVIVAL | ONCOLOGY | CLASSIFICATION | LEUKEMIA | AZACITIDINE | MDS | CYTOGENETICS | Models, Theoretical | Prognosis | Risk Assessment | Humans | Middle Aged | Myelodysplastic Syndromes - classification | Male | Survival Rate | Myelodysplastic Syndromes - diagnosis | Myelodysplastic Syndromes - therapy | Adolescent | Chromosome Aberrations | Aged, 80 and over | Adult | Female | Aged | Myelodysplastic Syndromes - genetics | Chromosomes, Human, Pair 7 - genetics | Blast Crisis | Models | Research | Health risk assessment | Myelodysplastic syndromes | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes
by Guillermo Garcia-Manero and Pierre Fenaux
Journal of Clinical Oncology, ISSN 0732-183X, 02/2011, Volume 29, Issue 5, pp. 516 - 523
Over the last decade, treatment approaches for patients with myelodysplastic syndromes (MDS) have improved significantly. Treatment of MDS is tailored to the... 
SURVIVAL | DECITABINE | INTENSIVE CHEMOTHERAPY | LOW-RISK | THERAPY | ONCOLOGY | DOSE ARA-C | VALPROIC ACID | ACUTE MYELOID-LEUKEMIA | AZACITIDINE | CLINICAL-RESPONSE | Prognosis | Erythropoietin - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Hematopoietic Stem Cell Transplantation | Azacitidine - analogs & derivatives | Recombinant Proteins | Transplantation, Homologous | Thalidomide - analogs & derivatives | Antimetabolites, Antineoplastic - therapeutic use | DNA Methylation | Myelodysplastic Syndromes - mortality | Epoetin Alfa | Thalidomide - therapeutic use | Myelodysplastic Syndromes - drug therapy | Azacitidine - therapeutic use | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
by Fenaux, Pierre, Prof and Mufti, Ghulam J, Prof and Hellstrom-Lindberg, Eva, Prof and Santini, Valeria, MD and Finelli, Carlo, MD and Giagounidis, Aristoteles, MD and Schoch, Robert, MD and Gattermann, Norbert, MD and Sanz, Guillermo, MD and List, Alan, Prof and Gore, Steven D, Prof and Seymour, John F, MBBS and Bennett, John M, Prof and Byrd, John, Prof and Backstrom, Jay, MD and Zimmerman, Linda, BSN and McKenzie, David, MS and Beach, CL, PharmD and Silverman, Lewis R, MD and Int Vidaza High-Risk MDS Survival and International Vidaza High-Risk MDS Survival Study Group
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 3, pp. 223 - 232
Summary Background Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the... 
Hematology, Oncology and Palliative Medicine | INTENSIVE CHEMOTHERAPY | RESPONSE CRITERIA | ONCOLOGY | DNA METHYLTRANSFERASE | CLASSIFICATION | LOW-DOSE CYTARABINE | ACUTE MYELOID-LEUKEMIA | STEM-CELL TRANSPLANTATION | ARA-C | INTERNATIONAL WORKING GROUP | CHROMOSOME-7 ABNORMALITIES | Azacitidine - adverse effects | Humans | Middle Aged | Proportional Hazards Models | Male | Antimetabolites, Antineoplastic - therapeutic use | Myelodysplastic Syndromes - mortality | Aged, 80 and over | Adult | Female | Aged | Myelodysplastic Syndromes - drug therapy | Azacitidine - therapeutic use | Antimitotic agents | Medical colleges | Care and treatment | Oncology, Experimental | Clinical trials | Research | Comparative analysis | Antineoplastic agents | Myelodysplastic syndromes | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Myelodysplastic Syndromes : Diagnosis - Prognosis - Therapy
by Platzbecker, Uwe and Fenaux, Pierre
06/2018, Hematologic Malignancies, ISBN 9783319768786, 154
The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted... 
Myelodysplastic syndromes-Treatment | Myelodysplastic syndromes-Diagnosis | Medicine & Public Health | Hematology | Oncology
eBook
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Dual origin of relapses in retinoic-Acid resistant acute promyelocytic leukemia
by Lehmann-Che, Jacqueline and Bally, Cécile and Letouzé, Eric and Berthier, Caroline and Yuan, Hao and Jollivet, Florence and Ades, Lionel and Cassinat, Bruno and Hirsch, Pierre and Pigneux, Arnaud and Mozziconacci, Marie-Joelle and Kogan, Scott and Fenaux, Pierre and De Thé, Hugues
Nature Communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 2047 - 8
Retinoic acid (RA) and arsenic target the t(15;17)(q24;q21) PML/RARA driver of acute promyelocytic leukemia (APL), their combination now curing over 95%... 
5'-Nucleotidase - genetics | Recurrence | Tretinoin - administration & dosage | Retinoic Acid Receptor alpha - genetics | Humans | Retinoic Acid Receptor alpha - metabolism | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - administration & dosage | fms-Like Tyrosine Kinase 3 - metabolism | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Promyelocytic, Acute - metabolism | Animals | Promyelocytic Leukemia Protein - metabolism | Mice | Arsenic Trioxide - administration & dosage | Leukemia, Promyelocytic, Acute - genetics | Mutation | 5'-Nucleotidase - metabolism | Leukemia, Promyelocytic, Acute - drug therapy | Promyelocytic Leukemia Protein - genetics | Regulators | Transcription | Arsenic | Leukemia | MAP kinase | Patients | Subgroups | Promyeloid leukemia | Chemotherapy | Passengers | Acids | Acid resistance | Remission | Diagnosis | Retinoic acid | Acute promyeloid leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text How we treat lower-risk myelodysplastic syndromes
by Fenaux, Pierre and Fenaux, Pierre and Ades, Lionel and Adès, Lionel
Blood, ISSN 0006-4971, 05/2013, Volume 121, Issue 21, pp. 4280 - 4286
Lower-risk myelodysplastic syndromes (MDSs) are defined as having low or intermediate 1 risk by the International Prognostic Scoring System and are... 
LEUKEMIA GROUP-B | PROGNOSTIC SCORING SYSTEM | COLONY-STIMULATING FACTOR | IRON CHELATION-THERAPY | BONE-MARROW | ANTITHYMOCYTE GLOBULIN | PHASE-II | TRANSFUSION-DEPENDENT PATIENTS | QUALITY-OF-LIFE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Thalidomide - analogs & derivatives | Anemia - epidemiology | Humans | Risk Factors | Angiogenesis Inhibitors - therapeutic use | Anemia - therapy | Antineoplastic Agents - therapeutic use | Thalidomide - therapeutic use | Myelodysplastic Syndromes - epidemiology | Myelodysplastic Syndromes - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study
by Cecile Pautas and Fatiha Merabet and Xavier Thomas and Emmanuel Raffoux and Claude Gardin and Selim Corm and Jean-Henri Bourhis and Oumedaly Reman and Pascal Turlure and Nathalie Contentin and Thierry de Revel and Philippe Rousselot and Claude Preudhomme and Dominique Bordessoule and Pierre Fenaux and Christine Terré and Mauricette Michallet and Hervé Dombret and Sylvie Chevret and Sylvie Castaigne
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 808 - 814
Purpose In patients with acute myeloid leukemia (AML), induction chemotherapy is based on standard doses of anthracyclines and cytarabine. High doses of... 
ADULT PATIENTS | CYTOSINE-ARABINOSIDE | ONCOLOGY-GROUP | ONCOLOGY | COMPETING RISK | FREE SURVIVAL | ACUTE MYELOGENOUS LEUKEMIA | CONSOLIDATION THERAPY | PHASE-3 TRIAL | TRIAL COMPARING IDARUBICIN | 1ST COMPLETE REMISSION | Recurrence | Risk Assessment | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Recombinant Proteins - administration & dosage | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Interleukin-2 - administration & dosage | Leukemia, Myeloid, Acute - drug therapy | Female | Idarubicin - administration & dosage | Aged | Interleukin-2 - analogs & derivatives | Daunorubicin - administration & dosage | Index Medicus | Life Sciences | Immunology
Journal Article
Details down arrow